To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Safety information (Adverse Event)
Timeframe: 14 days from the initiation of tolvaptan sodium phosphate treatment
Number of Special Situations
Timeframe: 14 days from the initiation of tolvaptan sodium phosphate treatment
Number of off-Label Use
Timeframe: 14 days from the initiation of tolvaptan sodium phosphate treatment
Incidence of Serious Adverse Event (e.g. resulting in death or life-threatening)
Timeframe: 14 days from the initiation of tolvaptan sodium phosphate treatment
Incidence of Non-serious Adverse Events (i.e. all Adverse Events that do not meet the definition of a serious Adverse Event)
Timeframe: 14 days from the initiation of tolvaptan sodium phosphate treatment